Effect of Simultaneous Integrated Boost Intensity-modulated Radiation Therapy on Patients with Local Advanced Esophageal Cancer
Objective:To explore the effect of simultaneous integrated boost intensity-modulated radiation therapy(SIB-IMRT)on patients with local advanced esophageal cancer.Method:A total of 100 patients with local advanced esophageal cancer admitted to the First Affiliated Hospital of Bengbu Medical College from April 2021 to April 2023 were selected.They were randomly divided into observation group and control group,50 cases in each group.Both groups were given Paclitaxel combined with Cisplatin chemotherapy,the control group was given conventional intensity-modulated radiation therapy(C-IMRT),the observation group was given SIB-IMRT.The clinical efficacy,tumor indexes,immune function before and after treatment and adverse reactions were compared between the two groups.Result:The total effective rate of the observation group was 88.00%,which was significantly higher than 70.00%of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of cytokeratin 19 fragment(CYFRA21-1),squamous cell carcinoma antigen(SCC),carcinoembryonic antigen(CEA)were decreased in both groups,and the levels of CYFRA21-1,SCC and CEA levels in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).After treatment,CD3+,CD4+,CD4+/CD8+ were decreased in both groups,CD8+ were increased in both groups,but CD3+,CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group,and CD8+ was lower than that in the control group,and the differences were statistically significant(P<0.05).The incidence of radiation esophagitis,radiation tracheitis,bone marrow suppression and gastrointestinal reactions in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).Conclusion:SIB-IMRT is more effective in the treatment of patients with local advanced esophageal cancer,which can not only reduce the expression of serum tumor indicators,reduce the influence of chemoradiotherapy on immune function,but also reduce the occurrence of adverse reactions.
万方数据
维普
